62 results
8-K
EX-99.2
TARA
Protara Therapeutics Inc
5 Apr 24
Entry into a Material Definitive Agreement
8:14am
) rate at the preliminary three-month assessment timepoint.
The Phase 2 open-label ADVANCED-2 trial is assessing intravesical TARA-002 in at least 102
8-K
EX-99.4
TARA
Protara Therapeutics Inc
5 Apr 24
Entry into a Material Definitive Agreement
8:14am
P=0.034 P=0.025 P=0.011 P=0.021 P=0.074 45 40 35 30 25 20 15 10 5 0 Choline 12 16 Assessment Week Placebo // // CLINICALLY MEANINGFUL IMPROVEMENT … of patient CRFs, data on file. Choline D/C'd Assessment Week S Means tderr) ange f aseli L (+/ - s of ch rom B ne of MRI - p= 0.4770 p= 0.0197 p= 0.0312 p
8-K
EX-10.1
TARA
Protara Therapeutics Inc
5 Apr 24
Entry into a Material Definitive Agreement
8:14am
and as to which adequate reserves have been provided. No assessment in connection with United States federal tax returns has been made against … and has paid all taxes due pursuant to such returns or all taxes due and payable pursuant to any assessment received by the Company and its
8-K
EX-99.1
w1mzubfyodq kuywjasx
13 Mar 24
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
8:05am
8-K
EX-99.1
5wnsl5ttjioh38wer7g4
28 Apr 23
Regulation FD Disclosure
8:10am
8-K/A
EX-99.1
7fezc3
19 Mar 20
Financial Statements and Exhibits
9:31pm